环磷腺苷-葡甲胺治疗慢性肺心病心肺功能不全多中心临床研究

A multicenter clinical study on clinical effects of meglumine cyclic adenylate in treating patients with chronic pulmonary heart disease

目的 观察环磷腺苷 葡甲胺 (心先安 )治疗慢性肺心病心肺功能不全的临床疗效。方法 将 785例慢性肺心病患者分为观察组和对照组 ,两组常规治疗相同 ,观察组加用环磷腺苷 葡甲胺注射液 ,疗程 5～ 10d。比较两组治疗后临床症状、体征、心电图、肺通气功能和动脉血气的改善程度。结果 观察组和对照组的临床症状和体征改善的有效率分别为 92 2 %和 73 6 % ;肺活量 (VC)较治疗前分别增加 (42 6± 12 3)ml和 (313± 145 )ml;一秒钟用力呼气量 (FEV1)分别增加 (134± 5 4)ml和 (95± 5 5 )ml;最大呼气流量 (PEF)分别增加 (0 78± 0 32 )L/s和 (0 47± 0 32 )L/s;动脉血氧分压(PaO2 )分别增加 (2 3 4± 9 5 )mmHg和 (17 3± 10 4)mmHg ;心电图有效率分别为 6 3 7%和 41 2 % ,两组比较差异有非常显著性 (P <0 0 1,P <0 0 5 )。结论 联合使用环磷腺苷 葡甲胺治疗慢性肺心病心肺功能不全有显著疗效。

Objective To observe the clinical effecs of meglumine cyclic adenylate(MCA) in treating patients with chronic pulmonary heart disease Methods 785 patients with chronic pulmonary heart disease were devided into two groups:MCA group and control group Both groups of patients were treated with the same ordinary methods ,but MCA was given in the MCA group The period of treatment was 5～7 days The degree of improvement in clinical symptoms, signs, ECG, pulmonary ventilation function and arteiral blood gas analysis of the two groups before and after treatment were compared Results The rates of improvement in clinical symptoms and signs were 92 2% and 73 6% in MCA group and control group respectively VC increased (426±123) ml and (313±145) ml respectively as compared with the values before the treatment FEV 1 increased (134±54) ml and (95±55) ml, PEF increased (0 78±0 32) L/s and (0 47±0 32) L/s and PaO 2 increased (23 4±9 5) mm Hg and (17 3±10 4) mm Hg respectively The rates of ECG impravement were 63 7% and 41 2% respectively There was significant difference between the two groups ( P <0 01 and 0 05) Conclusion Significant therapeutic effects were obtained in treating patients of chronic pulmonary heart disease with respiratory and cardiac failure by using ordinary treatment measures combinded with MCA injection